Litcius/Paper detail

Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial

Johan Maertens, Galia Rahav, Dong‐Gun Lee, Alfredo Ponce‐de‐León, Isabel Cristina Ramírez Sánchez, Н Н Климко, Anne Sonet, Shariq Haider, Juan D. Vélez, Issam Raad, Liang‐Piu Koh, Meinolf Karthaus, Jianying Zhou, Ronen Ben‐Ami, Mary Motyl, Seongah Han, Anjana Grandhi, Hetty Waskin

2021The Lancet276 citationsDOIOpen Access PDF

Topics & Concepts

MedicineVoriconazolePosaconazoleAspergillosisClinical endpointPopulationInternal medicineRandomized controlled trialSurgeryImmunologyAntifungalEnvironmental healthDermatologyAntifungal resistance and susceptibilityOcular Infections and TreatmentsFungal Infections and Studies
Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial | Litcius